Blockade of chemokine signaling in patients with multiple sclerosis.
Neurology
; 67(10): 1880-3, 2006 Nov 28.
Article
em En
| MEDLINE
| ID: mdl-17130431
ABSTRACT
We assessed the safety and efficacy of orally administered CC chemokine receptor 1 (CCR1) antagonist in 105 patients with relapsing/remitting MS (RRMS) in a 16-week, randomized, double-blind, placebo-controlled trial. The primary endpoint was the cumulative number of newly active lesions on serial MRI scans. Other MRI, immunologic, and clinical outcomes were also explored. No significant treatment difference was observed for any tested MRI variable. CCR1 does not contribute to initial leukocyte infiltration in RRMS.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Compostos de Fenilureia
/
Piperidinas
/
Quimiocinas
/
Receptores de Quimiocinas
/
Imunossupressores
/
Esclerose Múltipla
Tipo de estudo:
Clinical_trials
Limite:
Humans
Idioma:
En
Ano de publicação:
2006
Tipo de documento:
Article